1. Xie, Ruihui, Cheng, Liang, Huang, Ming, Chen, Xu, Lin, Tianxin. . NAT10 Drives Cisplatin Chemoresistance by Enhancing ac4C-Associated DNA Repair in Bladder Cancer. In Cancer research, 83, 1666-1683. doi:10.1158/0008-5472.CAN-22-2233. https://pubmed.ncbi.nlm.nih.gov/36939377/
2. Davis, T A, Loos, B, Engelbrecht, A-M. 2014. AHNAK: the giant jack of all trades. In Cellular signalling, 26, 2683-93. doi:10.1016/j.cellsig.2014.08.017. https://pubmed.ncbi.nlm.nih.gov/25172424/
3. Ghodke, Indrajeet, Remisova, Michaela, Furst, Audrey, Altmeyer, Matthias, Soutoglou, Evi. 2021. AHNAK controls 53BP1-mediated p53 response by restraining 53BP1 oligomerization and phase separation. In Molecular cell, 81, 2596-2610.e7. doi:10.1016/j.molcel.2021.04.010. https://pubmed.ncbi.nlm.nih.gov/33961796/
4. Zhao, Qijie, Jiang, Yu, Xiang, Shixin, Yi, Tao, Xiao, Zhangang. 2021. Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons. In Frontiers in immunology, 12, 658753. doi:10.3389/fimmu.2021.658753. https://pubmed.ncbi.nlm.nih.gov/33859650/